Better Therapeutics to Release Fourth Quarter and Full Year 2022 Finan...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve • Statement from Minister Hutchings on progress in support of rural Canadians • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5 • Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice • BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat • HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai • UNice Celebrates LGBTQ Pride Month • INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors • Bijou Ikli named new CEO by Florida Assisted Living Association • SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and • FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp • Rapid Dose Announces Proposed Private Placement Financing • The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit • Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS • INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors • Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open

Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023

SAN FRANCISCO , March 23 /Businesswire/ - Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its fourth quarter and full year 2022 financial results before the market opens on Thursday, March 30, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, March 30, 2023.

To access the conference call, please register at: https://register.vevent.com/register/BI24e91f91597f4f97a40e32c908ac7be5. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/cmdsh8s3. Following the webcast, a replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: investors.bettertx.com.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com